Predictions
Laboratory Corp. Of America (labcorp)
Start price
Target price
Perf. (%)
€189.00
08.07.23
08.07.23
-
08.07.24
08.07.24
5.11%
16.05.24
16.05.24
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€80.26
05.07.23
05.07.23
€93.60
05.07.24
05.07.24
-13.26%
24.05.24
24.05.24
Boston Scientific
Start price
Target price
Perf. (%)
€49.39
30.06.23
30.06.23
€58.68
30.06.24
30.06.24
42.74%
27.05.24
27.05.24
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€59.00
28.06.23
28.06.23
€64.04
28.06.24
28.06.24
-31.47%
27.05.24
27.05.24
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€85.44
24.06.23
24.06.23
€100.00
31.07.25
31.07.25
-18.52%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
AbbVie Inc.
Start price
Target price
Perf. (%)
€126.10
17.06.23
17.06.23
-
17.06.24
17.06.24
19.30%
27.05.24
27.05.24
Could be worthwhile Investment >10% per year
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€466.50
06.06.23
06.06.23
€600.00
06.06.24
06.06.24
1.19%
27.05.24
27.05.24
Leading role in innovation
Could be worthwhile Investment >10% per year
Some uniques
Small Risks for its business
Universal Health Services B
Start price
Target price
Perf. (%)
€127.00
02.06.23
02.06.23
€151.62
02.06.24
02.06.24
30.36%
27.05.24
27.05.24
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€307.95
30.05.23
30.05.23
€356.18
30.05.24
30.05.24
37.85%
27.05.24
27.05.24
Boston Scientific
Start price
Target price
Perf. (%)
€47.73
30.05.23
30.05.23
€54.08
30.05.24
30.05.24
47.71%
27.05.24
27.05.24
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
116.01%
27.05.24
27.05.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
9.86%
27.05.24
27.05.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued